N
Nathan Ford
Researcher at World Health Organization
Publications - 476
Citations - 25127
Nathan Ford is an academic researcher from World Health Organization. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 82, co-authored 455 publications receiving 21982 citations. Previous affiliations of Nathan Ford include Imperial College London & University of California, San Francisco.
Papers
More filters
Changes in rapid HIV treatment initiation after national “treat all” policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis
Olga Tymejczyk,Ellen Brazier,Constantin T. Yiannoutsos,Michael J. Vinikoor,Monique van Lettow,Fred Nalugoda,Mark Urassa,Jean d’Amour Sinayobye,Peter F Rebeiro,Kara Wools-Kaloustian,Mary-Ann Davies,Elizabeth Zaniewski,Nanina Anderegg,Grace Liu,Nathan Ford,Denis Nash +15 more
TL;DR: It is indicated that adoption of treat all policies had a strong effect on increasing rates of rapid ART initiation, and that these increases followed different trajectories across the 6 countries.
Journal ArticleDOI
XDR-TB in South Africa: detention is not the priority.
TL;DR: From the experience in South Africa, a number of challenges must be addressed locally and nationally to curb MDR-TB, including decentralization of services to the primary care level, reinforcing adherence through treatment literacy and a patient-centred approach, and community-based support.
Journal ArticleDOI
Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis
Steve Kanters,Francoise Renaud,Ajay Rangaraj,Ke Zhang,E. H. Limbrick-Oldfield,M. D. Hughes,Nathan Ford,Marco Vitoria +7 more
TL;DR: In this article , a systematic review aimed to compare body weight gain associated outcomes over time between dolutegravir (DTG)-based antiretroviral (ART) regimens to other ART regimens, to compare tenofovir alafenamide (TAF)-based regimens and to evaluate the associated prognostic factors.
Journal ArticleDOI
Provision and continuation of antiretroviral therapy during acute conflict: the experience of MSF in Central African Republic and Yemen
TL;DR: The experience of providing ART and implementing contingency plans during acute instability in the Central African Republic and Yemen provides further evidence that provision of HIV treatment and emergency drug stocks can be successfully provided to most patients in both conflict-affected settings.
Journal ArticleDOI
Loss to follow-up from antiretroviral therapy clinics: A systematic review and meta-analysis of published studies in South Africa from 2011 to 2015
TL;DR: South Africa should standardise a LTFU definition to aid in monitoring and evaluation of ART programmes, with the broader goal of improving patient outcomes.